Order Article Reprints

Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, et al. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. Cancers. 2021; 13(8):1964. https://doi.org/10.3390/cancers13081964

Ligorio, Francesca, Giovanni Fucà, Emma Zattarin, Riccardo Lobefaro, Luca Zambelli, Rita Leporati, Carmen Rea, Gabriella Mariani, Giulia V. Bianchi, Giuseppe Capri, and et al. 2021. "The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab" Cancers 13, no. 8: 1964. https://doi.org/10.3390/cancers13081964

Ligorio, F., Fucà, G., Zattarin, E., Lobefaro, R., Zambelli, L., Leporati, R., Rea, C., Mariani, G., Bianchi, G. V., Capri, G., de Braud, F., & Vernieri, C. (2021). The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. Cancers, 13(8), 1964. https://doi.org/10.3390/cancers13081964